Vise Technologies Inc. Invests $381,000 in Moderna, Inc. $MRNA

Vise Technologies Inc. bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,447 shares of the company’s stock, valued at approximately $381,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in Moderna by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock worth $1,226,335,000 after purchasing an additional 399,487 shares during the period. BlackRock Inc. purchased a new stake in shares of Moderna during the second quarter valued at approximately $2,142,877,000. Capital World Investors bought a new position in shares of Moderna in the fourth quarter worth approximately $378,299,000. Invesco Ltd. grew its holdings in shares of Moderna by 15.7% in the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after purchasing an additional 1,115,131 shares during the last quarter. Finally, Theleme Partners LLP increased its stake in shares of Moderna by 8.6% in the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock worth $217,100,000 after buying an additional 626,420 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. The trade was a 4.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is owned by corporate insiders.

Moderna Stock Performance

Moderna stock opened at $158.83 on Wednesday. The stock’s 50 day simple moving average is $72.29 and its two-hundred day simple moving average is $57.69. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The stock has a market cap of $63.41 billion, a price-to-earnings ratio of -19.88 and a beta of 0.91. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $176.66.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.13) EPS. As a group, analysts expect that Moderna, Inc. will post -6.18 earnings per share for the current fiscal year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Positive Phase 3 cancer-vaccine data remains the main catalyst. Moderna and Merck reported that intismeran, used with Keytruda, met key goals in the INTerpath-001 study of resected melanoma. The result is viewed as an important validation of Moderna’s mRNA technology because it reportedly showed benefit over Keytruda alone—the first positive late-stage readout for an mRNA-based cancer vaccine in this setting. Moderna’s personalized cancer vaccine shows promise
• Positive Sentiment: Analysts see a substantial opportunity. Wolfe Research estimates the melanoma and broader cancer-vaccine opportunity could reach approximately $9.2 billion, while other analysts have raised ratings and highlighted the long-term potential of intismeran. That has helped shift the investment narrative beyond Moderna’s declining COVID-19 business. MRNA Stock Jumps Past $150
• Positive Sentiment: Broader mRNA validation is supporting sentiment. The FDA’s approval of the first mRNA-based flu vaccine could improve perceptions of mRNA platforms and reinforce the value of related intellectual property, although the approval is not itself a direct Moderna product catalyst. FDA Approves First mRNA-Based Flu Vaccine
• Neutral Sentiment: Trading momentum is amplifying the move. A reported “Power Inflow” signal and unusually heavy volume indicate strong buying interest, but these technical indicators do not establish the vaccine’s long-term commercial value. Moderna Shares Rise After Trading Signal
• Negative Sentiment: Investors face significant execution and valuation risks. The cancer-vaccine evidence remains limited, and broader adoption could be constrained by manufacturing complexity, regulatory requirements, cost, competition and the need for additional data. Analysts also caution that Moderna’s pipeline and financial outlook remain challenging outside this program. Explainer on the Merck-Moderna Cancer Vaccine
• Negative Sentiment: Profit-taking and geopolitical concerns could increase volatility. Moderna previously fell as traders locked in gains after its extraordinary advance. CEO Stéphane Bancel also warned that China is investing heavily in biotechnology and mRNA, creating a potential long-term competitive threat. Moderna CEO Warns About China’s mRNA Investment

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MRNA. Citigroup increased their price target on shares of Moderna from $41.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Loop Capital set a $135.00 target price on shares of Moderna in a report on Wednesday, August 19th. Barclays raised their price target on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Morgan Stanley lifted their price target on shares of Moderna from $39.00 to $89.00 and gave the company an “equal weight” rating in a report on Thursday, August 20th. Four investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus target price of $74.31.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.